About the Company
immunic, inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, crohn's disease, and psoriasis. its lead development program is imu-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in phase 2 trial to treat crohn's disease. the company is also developing imu-935, an inverse agonist of rorgt; and imu-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. immu
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IMUX News
Immunic And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their ...
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune ...
Immunic (NASDAQ: IMUX)
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases.
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
NEW YORK, Feb. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic ...
Immunic reports successful 2023 and prepares for key 2025 milestones
Immunic Inc CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion following what he described as a successful 2023. Clinically, Immunic achieved positive results across its portfolio, including ...
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return ...
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
NEW YORK, Feb. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
About Immunic, Inc. Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune ...
Immunic reports successful 2023 and prepares for key 2025 milestones
Immunic Inc CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion following what he described as a successful 2023. Outlining the company's achievements, Dr Vitt noted the company strengthened its ...
Loading the latest forecasts...